Welcome to the Jason Carter Clinical Trials Website
Our website helps patients find clinical trials. We currently offer patient-friendly descriptions of leukemia and lymphoma trials. Early in 2018, we will be:
Adding patient-friendly trial descriptions for other blood cancers and disorders
Making improvements to the search tool
Expanding our educational resources
Didn't find a trial or need help? Contact our clinical trial specialist at 888-814-8610 or contact@ctsearchsupport.org.
Two drugs, iberdomide or lenalidomide, after autologous (your own cells) blood or marrow transplant (BMT) to prevent multiple myeloma from coming back (relapse)
To find out if iberdomide or lenalidomide can prevent relapse of multiple myeloma after autologous BMT
You may be able to join this trial if you:
Are 18 years old or older
Have multiple myeloma
Have had an autologous BMT within the past year
Do not have smoldering myeloma, solitary plasmacytoma or nonsecretory myeloma. Your doctor can tell you this
The myeloma has not relapsed or gotten worse after BMT
Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
Iberdomide and lenalidomide are drugs that block the growth of cancer cells by changing the immune system.
In this trial, you’ll be randomized to 1 of 2 groups. Once you’re randomized, you’ll be told what group you’re in:
Group 1 – Autologous BMT plus iberdomide
Group 2 – Autologous BMT plus lenalidomide
Randomized means doctors will use a computer to assign you to either group. A computer assigns you by chance, like flipping a coin or drawing a name out of a hat. You, your doctor or the clinical trial doctor won’t have any control over which group you’ll be assigned. This means you won’t be able to choose your group.
First, you'll get drugs to prepare your body for the collection of your own blood-forming cells:
On transplant day, your own blood-forming cells are given back to you through an IV infusion.
After transplant, you’ll get:
Iberdomide - Group 1 only – A pill that you take by mouth. The dose you'll get depends on when you start the trial and how safe it has been
Lenalidomide - Group 2 only - A pill that you take by mouth
You may continue treatment for as long as the clinical trial doctors think it’s best for your health. You'll have biopsies to see how well the treatment is working. The clinical trial doctors will check your health for up to 6 years.
The Food and Drug Administration (FDA) has approved all of the drugs used in this trial to treat multiple myeloma. Using iberdomide or lenalidomide after autologous BMT to prevent relapse of multiple myeloma is new and unproven.
Contacts
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com, 855-907-3286, Clinical.Trials@bms.com
First line of email MUST contain NCT # and Site #.
Locations
Rocky Mountain Cancer CentersRECRUITING
Aurora, Colorado John Burke, Site 0202, 303-925-0700
Cleveland ClinicRECRUITING
Weston, Florida Chakra Chaulagain, Site 0003, 954-487-2124
H. Lee Moffitt Cancer Center & Research InstituteRECRUITING
Tampa, Florida Melissa Alsina, Site 0192, 813-745-7202
Mayo Clinic FloridaRECRUITING
Jacksonville, Florida Sikander Ailawadhi, Site 0007, 904-953-0853
Tampa General HospitalRECRUITING
Tampa, Florida Ivan Borrello, Site 0308, 410-955-4967
Augusta University - Georgia Cancer CenterRECRUITING
Augusta, Georgia Amany Keruakous, Site 0021, 706-721-2505
The Winship Cancer Institute of Emory UniversityRECRUITING
Atlanta, Georgia Sagar Lonial, Site 0018, 404-778-1900
University Cancer Blood CtrRECRUITING
Athens, Georgia Charles Bodine, Site 0019
The University of Chicago Medical Center - Duchossois Center for Advanced MedicineRECRUITING
Chicago, Illinois Benjamin Derman, Site 0237, 847-275-8131
University of Kansas Cancer Center - The Richard and Annette Bloch Cancer Care PavilionRECRUITING
Westwood, Kansas Al-Ola Abdallah, Site 0015, 918-261-6196
